| Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. | |
| | |
MedLine Citation:
|
PMID: 23054001 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The use of lymphatic microvessel density (LVD) and pro-lymphangiogenic mediators as prognostic factors for survival in breast cancer remains controversial. We searched the electronic databases PubMed and EMBASE without language restrictions for relevant literature to aggregate the survival results. To be eligible, every study had to include the assessment of the LVD or the expression of vascular endothelial growth factor (VEGF)-C or -D in patients with breast cancer and provide a survival comparison, including disease-free survival (DFS) or overall survival (OS), according to the LVD, VEGF-C or VEGF-D status. Across all studies, 56.64 % of patients were considered to have a VEGF-C-positive tumor, and 65.54 % of patients had VEGF-D-positive tumors. High LVD had an unfavorable impact on DFS, with a pooled hazard ratio (HR) of 2.222 (95 % CI 1.579-3.126) and an OS with a HR of 2.493 (95 % CI 1.183-5.25). According to the different lymphatic makers, the subgroup HR in the D2-40 studies was 2.431 (95 % CI 1.622-3.644) for DFS and 4.085 (95 % CI 1.896-8.799) for OS. VEGF-C overexpression, as assessed by immunochemistry, was a prognostic factor for decreased DFS (HR 2.164; 95 % CI 1.256-3.729) and for decreased OS (HR 2.613; 95 % CI 1.637-4.170). VEGF-D overexpression was a significant although weak prognostic factor for DFS only when assessed by immunochemistry, with a HR of 2.108 (95 % CI 1.014-4.384). Our meta-analysis demonstrated that LVD, VEGF-C and VEGF-D could predict poor prognosis in patients with breast cancer. However, standardization of the assessment of LVD and for the expression of lymphangiogenesis factors is needed. |
| | |
Authors:
|
Jun Wang; Yan Guo; Baocheng Wang; Jingwang Bi; Kainan Li; Xiuju Liang; Huili Chu; Huihui Jiang |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-11 |
Journal Detail:
|
Title: Molecular biology reports Volume: - ISSN: 1573-4978 ISO Abbreviation: Mol. Biol. Rep. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0403234 Medline TA: Mol Biol Rep Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Oncology, General Hospital, Jinan Command of People's Liberation Army, Shifan Street 25, Tianqiao District, Jinan, 250031, China, ggjun2005@126.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from N...
Next Document: R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are rela...